Sarah Allford

Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias

Sarah Allford, Beverley J. Hunt, Peter Rose et al. · British Journal of Haematology · 2003 · 380 citations · Full text

Medicine, Hematology, Pathology +13

von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura

Sarah Allford, Paul Harrison, Andrew Lawrie et al. · British Journal of Haematology · 2000 · 94 citations

Medicine, Hematology, Pathology +17

Mutation analysis and clinical implications of von Willebrand factor–cleaving protease deficiency

K. Assink, Rikke H.M. Schiphorst, Sarah Allford et al. · Kidney International · 2003 · 91 citations · Full text

Medicine, Genetics, Molecular Genetics +17

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations

Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman et al. · Journal of Clinical Oncology · 2024 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML

Sarah Allford, David Grimwade, Stephen E. Langabeer et al. · British Journal of Haematology · 1999 · 38 citations

Life Sciences, Hematology, Molecular Biology +17